TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11152432
Drug: 3 day
Normalized name: Kathro 3 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 day regimen of azithromycin (500 mg/day)
Study: 9471423
Drug: Octreotide 100
Normalized name: 1 ML octreotide 100 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 100 micrograms subcutaneously, three times daily for two days
Study: 7952561
Drug: Topical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobial prophylaxis (TAP) with tobramycin, colistin, and amphotericin B administered in oropharynx and stomach.
Study: 7952561
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical antimicrobial prophylaxis (Control Group 2).
Study: 7952561
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical antimicrobial prophylaxis (Control Group 3).
Study: 7952561
Drug: Topical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobial prophylaxis (TAP) (Group 1).
Study: 3608351
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg intravenous trazodone
Study: 3608351
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral trazodone
Study: 30425247
Drug: Low-gluten diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-gluten diet (2 g gluten per day)
Study: 30425247
Drug: High-gluten diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-gluten diet (18 g gluten per day)
Study: 27076370
Drug: Lidocaine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (intravenous bolus of 1.5 mg/kg at induction of anesthesia, followed by an infusion of 1.5 mg · kg · h until 30 minutes after PACU arrival)
Study: 22251024
Drug: Other sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other sleep medications
Study: 18399256
Drug: Oral immunonutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunonutrition (Impact Oral) for 7-10 days before surgery
Study: 10066840
Drug: Nadroparin (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (180 anti-factor Xa units/kg per 24 hours) for 3 weeks followed by oral anticoagulants for 3 months
Study: 7030714
Drug: 5-nitrox (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-nitrox (200 to 250 mg, mean 3 mg/kg of body weight)
Study: 7030714
Drug: 5-nok (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-nok (administered under the same conditions)
Study: 17910331
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray, 1 spray per nostril twice daily
Study: 15475903
Drug: Cyclo-oxygenase-2 (COX-2)
Normalized name: STP705 (small interfering RNA (siRNA) therapeutic directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclo-oxygenase-2 (COX-2) inhibitors
Study: 15475903
Drug: Paracetamol 600/650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 600/650 mg plus codeine 60 mg
Study: 9760898
Drug: TiO‐blasted implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: TiO‐blasted implants
Study: 9760898
Drug: Both types
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both types of implants
Study: 7802196
Drug: Plasma‐Lyte 148
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma‐Lyte 148 (magnesium‐containing crystalloid solution)
Study: 7802196
Drug: Compound sodium
Normalized name: SODIUM CHLORIDE 6 g in 1 L / SODIUM LACTATE 3.22 g in 1 L / POTASSIUM CHLORIDE 400 mg in 1 L / CALCIUM CHLORIDE 270 mg in 1 L INTRAVENOUS INJECTION, SOLUTION [COMPOUND SODIUM LACTATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound sodium lactate solution (maintenance crystalloid)
Study: 31218842
Drug: Neoadjuvant dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant dual anti-HER2 therapy and taxane
Study: 22592572
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg vitamin C daily
Study: 18689550
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diet and exercise (DE)
Study: 11433088
Drug: CT (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (Conventional Treatment)
Study: 11433088
Drug: CTM (Conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTM (Conventional Treatment with 2 Anorectal Manometry sessions)
Study: 9609557
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy with glucocorticoids
Study: 9609557
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy without glucocorticoids
Study: 8054247
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) 250 mg orally
Study: 8054247
Drug: Dideoxyinosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dideoxyinosine (ddI) 250 mg orally
Study: 8054247
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ZDV 250 mg plus ddI 250 mg orally
Study: 2455426
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil lotion (2% and 5%)
Study: 2455426
Drug: Placebo minoxidil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo minoxidil lotion
Study: 28772041
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) therapy
Study: 10847236
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two risk factors
Study: 10847236
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three risk factors
Study: 27809848
Drug: Conventional anti-diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anti-diabetic agents
Study: 31159796
Drug: Well-being therapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Well-being therapy (WBT) for 5 weeks, n=39
Study: 31159796
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control condition (CC) for 5 weeks, n=48
Study: 25881796
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (single dose)
Study: 24680087
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) - intravenous 1 g bolus, 1 g infusion/8 h
Study: 22001815
Drug: Rinsing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinsing with 2 ml of balanced saline solution
Study: 19155004
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus cyclic medroxyprogesterone acetate (MPA) 5 mg twice a day
Study: 17519068
Drug: bimatoprost/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: bimatoprost/timolol fixed combination (BTFC)
Study: 17519068
Drug: latanoprost/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: latanoprost/timolol fixed combination (LTFC)
Study: 9094726
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of nebulized ipratropium added to three albuterol nebulizations administered over 1 hour
Study: 9094726
Drug: 0 doses
Normalized name: mometasone furoate 220 mcg/actuation (30 doses) INHALATION AEROSOL POWDER, BREATH ACTIVATED (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 doses of nebulized ipratropium added to three albuterol nebulizations administered over 1 hour
Study: 7682029
Drug: Risperidone 4-12
Normalized name: risperidone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4-12 mg
Study: 30425014
Drug: Buzzy (thermomechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buzzy (thermomechanical stimulation) during injection
Study: 27634091
Drug: Connective tissue
Normalized name: Connective tissue protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Connective tissue manipulation (CTM) twice per week for 6 weeks
Study: 27634091
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (CG)
Study: 23875818
Drug: Prophylactic single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic single-dose antibiotic administered preoperatively
Study: 23875818
Drug: Prophylactic single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic single-dose antibiotic administered at cord clamping
Study: 20921085
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/day) 3 weeks before surgery
Study: 20921085
Drug: Methylprednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (10 mg/kg, single shot)
Study: 14620117
Drug: MTX microtextured
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX microtextured implant surfaces
Study: 14620117
Drug: Machined implant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machined implant surfaces
Study: 10928438
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% caudally (0.5 mL kg(‐1))
Study: 10928438
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% caudally (0.5 mL kg(‐1)) + Clonidine (1 microg kg(‐1))
Study: 10928438
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% caudally (0.5 mL kg(‐1)) + Sufentanil (0.5 microg kg(‐1))
Study: 10928438
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% caudally (0.5 mL kg(‐1)) + Clonidine (0.5 microg kg(‐1)) + Sufentanil (0.25 microg kg(‐1))
Study: 8909667
Drug: Inhaled aerosolized
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aerosolized prostacyclin 50 ng/kg/min
Study: 28841847
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are activated (e.g., ask questions, express opinions, ask for clarification)
Study: 24460069
Drug: Daily walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily walking intervention (10,000 steps per day and a weekly supervised group walk) for 10 weeks
Study: 24460069
Drug: Daily walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily walking intervention
Study: 19709327
Drug: Aqueous leaf
Normalized name: Belladonna Leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous leaf extracts of Syzygium cumini (ASC) at 60-1000 microg/mL
Study: 12377799
Drug: 2.5 micro
Normalized name: Digoxin 62.5 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 micro g LT
Study: 12377799
Drug: 0.5 micro
Normalized name: calcitriol 0.5 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 micro g LT
Study: 12377799
Drug: 0.1 micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 micro g LT
Study: 10199429
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens, 1.25 mg/d for 21 days
Study: 7754476
Drug: Homeopathic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatments (various drugs prescribed by homeopathic physicians)
Study: 30303664
Drug: Dalargin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalargin therapy (2 mg/day for 10 days, 3 courses during 3 months)
Study: 19514183
Drug: needle‐rolling therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: needle‐rolling therapy
Study: 16772810
Drug: Olanzapine 5
Normalized name: olanzapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 5 mg/d (increased to mean 10.55 mg/d)
Study: 16772810
Drug: Olanzapine 20
Normalized name: olanzapine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 20 mg/d (fixed dose)
Study: 15618849
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy during colonoscopy
Study: 11819728
Drug: Hepatic artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic artery ligation (HAL) and/or hepatic artery infusion (HAI) (Group B)
Study: 11819728
Drug: Transcatheter hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter hepatic arterial chemoembolization (TACE) or HAI and/or portal vein infusion (PVI) after operation (Group D)
Study: 9247243
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (blast type)
Study: 7509784
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Trasylol (Hammersmith dosage: 6 x 10(6) KIU)
Study: 7509784
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Trasylol (half of Hammersmith dosage)
Study: 7509784
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Trasylol
Study: 7509784
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Trasylol
Study: 7509784
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Trasylol and Low Dose Trasylol
Study: 2959236
Drug: Captopril (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (average dosage 265 mg/d, range 150-300 mg)
Study: 2959236
Drug: Minoxidil (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil (average dosage 19.6 mg/d, range 7.5-30 mg)
Study: 31948461
Drug: Aspirin (n
Normalized name: ACETAMINOPHEN 250 mg / ASPIRIN 250 mg / CAFFEINE 65 mg ORAL TABLET, FILM COATED [EXCEDRIN MIGRAINE acetaminophen, aspirin (nsaid) and caffeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (n = 40)
Study: 23533254
Drug: Intrathecal clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal clonidine (0-100 µg)
Study: 23533254
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine (0-8.8 mg)
Study: 20592725
Drug: Ferumoxytol (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol (two 510 mg doses administered 24 h apart)
Study: 16841666
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and multi-glycosides of tripterygii (MT)
Study: 8545138
Drug: Methadone (custom-made
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (custom-made capsules)
Study: 8545138
Drug: Methadone (suppositories)
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone (suppositories)
Study: 1902052
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin (ECA) 325 mg
Study: 18760125
Drug: Patient self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient self-management (SM) skills training in combination with HF education
Study: 15973062
Drug: Oral ramosetron
Normalized name: alosetron Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ramosetron
Study: 15973062
Drug: Dopamine D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2 receptor-blocker (historical control)
Study: 12204841
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with saquinavir soft gel, zalcitabine and zidovudine for 52 weeks
Study: 12204841
Drug: Baseline viral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline viral load and development of genotypic mutations on therapy
Study: 12204841
Drug: Plasma saquinavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma saquinavir concentration < 50 mg/ml at 4 weeks
Study: 8803522
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg orally
Study: 8803522
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg orally
Study: 8803522
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg intravenously
Study: 1618070
Drug: Cisapride (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (2.5 mg and 5 mg)
Study: 6705640
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg sublingually/buccally)
Study: 6705640
Drug: Propantheline bromide
Normalized name: Propantheline Bromide
DrugBank: Propantheline (DB00782)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propantheline bromide (15 mg orally)
Study: 6705640
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine and propantheline bromide
Study: 26908401
Drug: Edoxaban (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (high-dose edoxaban regimen - 60 mg daily; lower-dose edoxaban regimen - 30 mg daily) with SAPT (aspirin 92.5%)
Study: 26908401
Drug: Edoxaban (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (high-dose edoxaban regimen)
Study: 26908401
Drug: Edoxaban (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (high-dose edoxaban regimen) with SAPT
Study: 26908401
Drug: Warfarin without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin without SAPT
Study: 26908401
Drug: Warfarin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin with SAPT
Study: 26908401
Drug: Edoxaban (lower-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (lower-dose edoxaban regimen) without SAPT
Study: 26908401
Drug: Edoxaban (lower-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (lower-dose edoxaban regimen) with SAPT
Study: 25089537
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral dose of 0.875 mg vitamin D₃ (vitD₃)
Study: 18545061
Drug: 120 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/day of extract of ginkgo biloba (EGb) for 12 weeks
Study: 8701398
Drug: Hirudin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (10, 15 or 20 mg s.c. b.i.d.)
Study: 8701398
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5000 IU s.c. t.i.d.)
Study: 1649267
Drug: Chemotherapy (CE'P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CE'P and MEC' regimens)
Study: 6378303
Drug: Clorgyline (monoamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorgyline (monoamine oxidase inhibitor)
Study: 30777471
Drug: Resveratrol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (400 mg) for 12-14 weeks
Study: 21725047
Drug: Nonmyeloablative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmyeloablative chemotherapy
Study: 18290397
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous deferoxamine (130 mg/kg per day over 10-14 hours for 5 consecutive days)
Study: 18290397
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous deferoxamine
Study: 15471837
Drug: 99mTc‐pertechnetate per‐rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐pertechnetate per‐rectal portal scintigraphy (PPS)
Study: 11387540
Drug: Self-help kit
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help kit and fully covered benefits for OTC nicotine replacement therapy (NRT) gum and patch, and participation in a group behavioural cessation programme with no patient cost sharing
Study: 9263614
Drug: Ipriflavone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone (3 x 200 mg/day)
Study: 8280818
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole once daily (second 4 weeks)
Study: 8280818
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole once daily (second 4 weeks)
Study: 8280818
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole (4 weeks) then 20 mg (second 4 weeks)
Study: 8280818
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole (4 weeks) then 40 mg (second 4 weeks)
Study: 30644785
Drug: CHO group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO group (800 ml the evening before and 400 ml 2 hours before anesthesia)
Study: 26380366
Drug: Psychoeducational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational program (12 weekly 1.5-hour sessions)
Study: 23412645
Drug: Learning Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Learning Therapy (cognitive intervention program)
Study: 17324377
Drug: Tooth preparation
Normalized name: porcine tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth preparation for full crown and application of one‐step self‐etch adhesive (iBond Gluma inside)
Study: 9835498
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (3 microgram/kg/min)
Study: 8528892
Drug: Spironolactone (type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (type I glucocorticoid receptor antagonist), administered in increasing doses, orally.
Study: 8528892
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered orally.